首页> 外文期刊>The International journal of biological markers >Clinical Utility of Serum Tumor Markers in the Diagnosis of Malignant Intestinal Occlusion. A Prospective Observational Study
【24h】

Clinical Utility of Serum Tumor Markers in the Diagnosis of Malignant Intestinal Occlusion. A Prospective Observational Study

机译:血清肿瘤标志物在恶性肠梗阻诊断中的临床应用。前瞻性观察研究

获取原文
           

摘要

The aim of the present observational study was to evaluate the diagnostic accuracy of CEA, CA 19-9 and CA 72-4 in patients with bowel obstruction. One-hundred three patients admitted to an emergency unit with clinical and radiological signs of intestinal occlusion of unknown origin were prospectively studied. Patients submitted to emergency surgery were excluded. All patients underwent standard diagnostic procedures and serological assay of tumor markers. Colorectal cancer was diagnosed in 22 patients (21.4%), while 81 patients (78.6%) presented a benign condition. The sensitivity of CEA, CA 19-9 and CA 72-4 for colorectal cancer was 36.4%, 31.8% and 9.1%, respectively. Marker specificity was 91.4%, 90.1% and 95.1%, respectively. The combination of CEA and CA 19–9 increased the sensitivity to 45.5% but decreased the specificity to 83.9%. The overall accuracy was 79.6%, 77.7% and 76.7%, respectively. All positive cancer cases had advanced disease. All patients with CEA levels 10 ng/mL or CA 19-9 100 U/mL had colorectal cancer. Even in a highly selected population, tumor marker sensitivity was rather low and specificity incomplete. However, elevated levels may guide the diagnostic and therapeutic course in patients with obstructing colorectal cancer.
机译:本观察性研究的目的是评估CEA,CA 19-9和CA 72-4对肠梗阻的诊断准确性。前瞻性研究了入院至急诊室的一百三十三名临床和影像学特征未知的肠梗阻患者。排除接受急诊手术的患者。所有患者均接受了肿瘤标志物的标准诊断程序和血清学检测。大肠癌确诊为22例(21.4%),而81例(78.6%)为良性。 CEA,CA 19-9和CA 72-4对结直肠癌的敏感性分别为36.4%,31.8%和9.1%。标记物特异性分别为91.4%,90.1%和95.1%。 CEA和CA 19–9的组合将敏感性提高到45.5%,但特异性降低到83.9%。总体准确度分别为79.6%,77.7%和76.7%。所有阳性癌症病例均患有晚期疾病。所有CEA水平> 10 ng / mL或CA 19-9> 100 U / mL的患者均患有大肠癌。即使在高度选择的人群中,肿瘤标志物的敏感性仍然很低,并且特异性不完整。但是,升高的水平可能会指导结直肠癌患者的诊断和治疗过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号